The Australian company is engaged in the development, manufacture and marketing of biopharmaceutical products for the treatment and prevention of serious human medical conditions. It was founded in 1916 under the name Commonwealth Serum Laboratories. It was the first in Australia's public to supply life-saving products as insulin, penicillin, and polio vaccine. The company has its registered business headquarters located in Parkville, Victoria. Its major facilities are based in Australia, Germany, Switzerland and the United States of America.The company specializes in vaccines and plasma protein biotherapies. Under its plasma products, it offers immunoglobulins for the treatment of infections, autoimmune diseases and for the prevention of haemolytic disease in newborn babies. It also has plasma volume expanders for acute blood loss and severe burns, as well as clotting factors for bleeding disorders. Its Biotherapies segment offers influenza vaccine globally. It markets a wide range of vaccines, antivenoms and pharmaceutical products in Australia and New Zealand.The company continues to develop and improve product life cycle through global innovation and academic collaboration. It has built strategic partnerships with academic institutions and other corporations in Australia, North America and Europe for both basic and applied research in plasma therapeutics, vaccines and recombinant biotechnology.